SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Ribas, Antoni; Medina, Theresa; Kummar, Shivaani; Amin, Asim; Kalbasi, Anusha; J. Drabick, Joseph; Barve, Minal; A. Daniels, Gregory; Jean Lee Wong, Deborah; V. Schmidt, Emmett; F. Candia, Albert; L. Coffman, Robert; C.F. Leung, Abraham; S. Janssen, Robert

doi:10.1158/2159-8290.cd-18-0280

Public

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Published in Cancer Discovery • Aug 28, 2018

Authors:

Antoni Ribas

Theresa Medina

Shivaani Kummar

Abstract

Abstract PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or m...

Subject

Pembrolizumab

Multicenter study

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!